Isatuximab
- Generic Name
- Isatuximab
- Brand Names
- Sarclisa
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1461640-62-9
- Unique Ingredient Identifier
- R30772KCU0
- Background
Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line. Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic antibody targeted against CD38, a glycoprotein found on th...
- Indication
Isatuximab is indicated in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma in adults who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. It is also indicated in combination carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple ...
- Associated Conditions
- Multiple Myeloma (MM), Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 43
- Registration Number
- NCT05123131
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
🇮🇪Beaumont Hospital, Dublin, Ireland
🇮🇪Mater Misericordiae University Hospital, Dublin, Ireland
Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Intergroupe Francophone du Myelome
- Target Recruit Count
- 46
- Registration Number
- NCT05066607
- Locations
- 🇫🇷
CHRU - Hôpital du Bocage, Angers, France
🇫🇷CHU Caen - Côte de Nacre, Caen, France
🇫🇷Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France
Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Tufts Medical Center
- Registration Number
- NCT04943302
MInimal Residual Disease Adapted Strategy
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Intergroupe Francophone du Myelome
- Target Recruit Count
- 791
- Registration Number
- NCT04934475
- Locations
- 🇫🇷
Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre, Strasbourg, France
🇷🇪CHU de La Réunion site Sud, Saint-Pierre, Réunion
🇫🇷CHU Amiens Sud, AMIENS Cedex 1, France
Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease
- Conditions
- Interventions
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 1
- Registration Number
- NCT04912427
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT04850599
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy
- Conditions
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Won Seog Kim
- Target Recruit Count
- 37
- Registration Number
- NCT04763616
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Kangnamgu, Korea, Republic of
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).
- Conditions
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Poitiers University Hospital
- Target Recruit Count
- 270
- Registration Number
- NCT04751877
- Locations
- 🇫🇷
CHU Poitiers, Poitiers, France
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Jacob Laubach, MD
- Target Recruit Count
- 52
- Registration Number
- NCT04653246
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 197
- Registration Number
- NCT04643002
- Locations
- 🇮🇱
Investigational Site Number : 3760002, Jerusalem, Israel
🇫🇷Investigational Site Number : 2500002, Lille, France
🇫🇷Investigational Site Number : 2500001, Nantes, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.